Assuming the community cardiologist is able to obtain reimbursement for PCSK9 inhibitors, in what segment of your patient population do you think this therapy is most under-utilized? How do price reductions for these agents affect your approach?

Assuming the community cardiologist is able to obtain reimbursement for PCSK9 inhibitors, in what segment of your patient population do you think this therapy is most under-utilized? How do price reductions for these agents affect your approach?

CLICK HERE FOR CME CREDIT

Assuming the community cardiologist is able to obtain reimbursement for PCSK9 inhibitors, in what segment of your patient population do you think this therapy is most under-utilized? How do price reductions for these agents affect your approach?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology) Mount Sinai Icahn School of Medicine Director, Cardiometabolics Unit Mount Sinai Heart Institute New York, NY